Darlene Dobkowski, MA

Articles

PFS Improved With Niraparib Maintenance in BRCA+ Ovarian Cancer

June 4th 2021

Maintenance therapy with niraparib significantly improved progression-free survival in patients with BRCA-mutated ovarian cancer, according to results from three phase 3 trials.

States With Lower Medicaid Eligibility Limits May Have Worse Survival Rates Among Patients with Cancer

May 19th 2021

Patients with cancer who live in states with lower Medicaid income eligibility limits had worse long-term survival outcomes compared with those with higher eligibility limits.

Higher Lenvatinib Dose May Improve QoL in RCC

February 11th 2021

February 11, 2021 - A higher starting dose of lenvatinib — 18 mg per day — improved health-related quality of life and led to longer time to deterioration compared with a lower starting dose of lenvatinib — 14 mg per day — in patients with renal cell carcinoma.

Clinicians May Need to Further Educate Their Patients About Treatment Options During Decision-Making Process

January 28th 2021

January 28, 2021 - Although survivors and patients with lung cancer felt that they were involved in the treatment decision-making process, nearly half of them reported that they knew what their treatment options were before making a decision.

Invasive Gastrointestinal Stromal Tumors More Common in Men, Initiating in the Small Intestine and Stomach

January 15th 2021

January 15, 2021 - Findings from an analysis determined that stage 4 gastrointestinal stromal tumors were rare and led to hepatic metastases, although overall survival was up to 51% at 5 years.

Combination Therapy with Tesetaxel and Capecitabine Improves PFS in HER2-, HR+ Metastatic Breast Cancer

December 11th 2020

December 11, 2020 - Patients with human epidermal growth factor receptor 2-negative, hormone receptor-positive metastatic breast cancer who were treated with tesetaxel and a reduced dose of capecitabine experienced improvements in progression-free survival compared with those treated with the FDA-approved dose of capecitabine alone.

Greater Adherence to a Diet for Diabetes Reduction May Improve Survival for Breast Cancer

December 10th 2020

December 10, 2020 - Women with stage 1 to 3 breast cancer who adhered to a diabetes risk reduction diet had improved survival versus those who did not follow this specific diet.

Survival Benefit of Venetoclax and Rituximab in Relapsed/Refractory CLL Persists Out to Five Years

December 5th 2020

December 5, 2020 - Patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax and rituximab had a sustained progression-free survival and overall survival benefit at five years compared with those treated with bendamustine and rituximab.